iBET has several established collaborations with national and international Pharma companies.
Over the last 20 years, iBET has been developing several projects for international pharmaceutical companies, such as Bayer, Novartis, Merck, Sanofi, Abbvie, Apceth, AstraZeneca, Glaxo-Smith-Kline, Merck & Co., among others.
R&D programs main areas include:
- process development for protein production (including Monoclonal Antibodies);
- production of virus-based vaccines; viral vectors for gene therapy (Retrovirus and Lentivirus, Adenovirus, Adeno Associated Virus and Baculovirus);
- development of tools and methodologies for cell therapy applications and pre-clinical research (novel 3D in vitro models for toxicology and disease models), namely the use of Stem Cells (hESC, Adult Stem Cells and iPS); and
- primary cultures of human hepatocytes, cancer and brain cells.
Alloksys, The Netherlands
Applied Sensor, Sweden
Boheringer Ingelheim, Germany
Crucell, The Netherlands
EMD Millipore, USA
Glaxo Smith Kline
Janssen Biotech-Johnson & Johnson, USA
Janssen-Cilag GmbH International
Merck Healthcare KGaA, Germany
Novo Nordisk, Denmark
Pall Life Sciences, USA
PBS Biotech, USA
Sumitomo Dainippon Pharma, Japan